Sitemap
Pages
- Allan Balmain, PhD, FRSE
- Archive
- Brian Bronk, PhD
- Careers
- Company
- Edwin Cuppen, PhD – scientific co-founder InteRNA
- Emile Voest, MD, PhD (chairman)
- Enabling next-generation drug delivery technology
- Eugene Berezikov, PhD – scientific co-founder InteRNA
- Fiona Maclaughlin, PhD
- Graham Dixon, PhD
- Hans Schikan, PharmD, chairman
- Identification mode of action & biomarkers
- Introduction
- Investors
- Jaap Verweij, MD, PhD
- Karl Rothweiler, MBA
- Leadership
- Lentiviral-based miRNA overexpression library
- Mark Vaeck, PhD
- miRNAs and cancer
- Products
- Samuel Gerssen, MSc, MBA
- Scientific advisory board
- Scientific publications
- Search
- Supervisory board
- Technology & IP
- Unique IP position
- William (Bill) Hahn, MD, PhD
Publications
- CATO SMS Signs Agreement with InteRNA to Facilitate Phase I Solid Tumor Trial
- InteRNA and the renewed interest in RNA therapeutics in the March 2021 edition of MedNous
- InteRNA and UMC Utrecht Publish Preclinical Evidence for Potential of miRNAs in Treatment of Epilepsy
- InteRNA Appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board
- InteRNA builds Management Team for next stage of development
- InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting
- InteRNA in de Kerstbijlage van het Algemeen Dagblad d.d. 17 december 2020: Nieuwe vorm van immunotherapie helpt bij de bestrijding van kanker.
- InteRNA presents data on drug formulation and mode of action of lead oncology development candidate INT-1B3 at the 15th annual OTS meeting
- InteRNA presents data on potential of lead oncology development candidate INT-1B3 in immuno-oncology at the SelectBIO Immuno-Oncology Europe 2019 meeting
- InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting
- InteRNA steunt de campagne Innovaties in Oncologie van @Mediaplanet. Leer meer over verschillende innovaties in oncologie zoals immuuntherapieën van thought leaders, zoals Ton Schumacher online of in de New Scientist (24 maart 2020)
- InteRNA Technologies also receives notice of allowance for its melanoma lead compound miRNA-3157 in Australia
- InteRNA Technologies and Cenix BioScience Ink Research Agreement for miRNA Drug Discovery
- InteRNA Technologies and Dana-Farber Cancer Institute to collaborate on the role of microRNAs in cancer pathways
- InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer
- InteRNA Technologies and VU University Medical Center to Develop microRNA-based Diagnostics and Therapeutics for Cancer
- InteRNA Technologies Announces Dosing of First Patient in First-in-Human Trial of microRNA Drug Candidate INT-1B3 in Patients with Advanced Solid Tumors
- InteRNA Technologies announces establishment of Scientific Advisory Board Utrecht (the Netherlands)
- InteRNA Technologies announces establishment of Supervisory Board
- InteRNA Technologies Awarded € 2.7M Clinical Innovation Credit from Dutch Government
- InteRNA Technologies Awarded EUR 1.3 million Innovation Credit from Dutch Government Utrecht (the Netherlands)
- InteRNA Technologies B.V. announces full consolidation of its subsidiary InteRNA Genomics B.V. as of July 1, 2012
- InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M
- InteRNA Technologies Joins European SIROCCO Consortium to Study RNA Silencing
- InteRNA Technologies partner in €11.5 Million EU Framework Program 7
- InteRNA Technologies Publishes Preclinical Data from Investigational microRNA INT-1B3 Program in Molecular Therapy – Nucleic Acids and Oncotarget
- InteRNA Technologies receives notice of allowance for miRNA sequences of its lead pre-clinical product
- InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors
- InteRNA Technologies secures final extension Series A financing and strengthens its Supervisory Board
- InteRNA Technologies Strengthens its R&D Team Nijmegen/Utrecht (the Netherlands)
- InteRNA Technologies, UCB and University of Bonn to collaborate on the role of microRNAs in neurodegenerative disease
- InteRNA to Present Preclinical Proof-of-Concept Data on Lead microRNA Candidate INT-1B3 at 2018 AACR Annual Meeting
- InteRNA’s R&D collaboration partner UMC St. Radboud receives grant from Stichting voor de Technische Wetenschappen
- MiRacle Consortium led by InteRNA Technologies and VU University Medical Center
- New Cancer Research paper on the Mode of Action of one of our proprietary miRNA drug candidates for the treatment of epithelial cancers by UMC radboud icw InteRNA Technologies under our STW grant program
- New Journal of Neuroscience paper shows that our functional screening platform for miRNA drug candidates works also nicely outside Oncology
- New small and medium enterprises join TIPharma by signing two new projects
- Recently a short movie about InteRNA and it’s lead compound for the treatment of cancer was broadcasted in the RTL4/RTLZ program “Zo kan het ook”. Watch the video with the latest news here
- Silence Therapeutics and InteRNA Technologies sign collaboration to develop novel microRNA therapeutics
- SomantiX B.V. and InteRNA Technologies B.V. obtain a MIT R&D collaboration grant
- Vacancy for a highly motivated PhD student to join the RnD Research team with a keen interest on “ The endo-lysosomal processes in metabolic disease development and therapeutic efficacy”